AU2009313167C1 - Use of EEF1A as biomarker for screening of MetAP2 inhibitors - Google Patents
Use of EEF1A as biomarker for screening of MetAP2 inhibitors Download PDFInfo
- Publication number
- AU2009313167C1 AU2009313167C1 AU2009313167A AU2009313167A AU2009313167C1 AU 2009313167 C1 AU2009313167 C1 AU 2009313167C1 AU 2009313167 A AU2009313167 A AU 2009313167A AU 2009313167 A AU2009313167 A AU 2009313167A AU 2009313167 C1 AU2009313167 C1 AU 2009313167C1
- Authority
- AU
- Australia
- Prior art keywords
- metap2
- meteef1a
- activity
- compounds
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08019432.7 | 2008-11-06 | ||
| EP08019432 | 2008-11-06 | ||
| PCT/EP2009/007102 WO2010051882A1 (en) | 2008-11-06 | 2009-10-05 | Use of eef1a as biomarker and a method of screening metap2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2009313167A1 AU2009313167A1 (en) | 2011-06-23 |
| AU2009313167B2 AU2009313167B2 (en) | 2013-12-12 |
| AU2009313167C1 true AU2009313167C1 (en) | 2014-06-12 |
Family
ID=41409225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009313167A Active AU2009313167C1 (en) | 2008-11-06 | 2009-10-05 | Use of EEF1A as biomarker for screening of MetAP2 inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9151743B2 (enExample) |
| EP (1) | EP2344665B1 (enExample) |
| JP (1) | JP5347028B2 (enExample) |
| AU (1) | AU2009313167C1 (enExample) |
| CA (1) | CA2742737C (enExample) |
| ES (1) | ES2402564T3 (enExample) |
| IL (1) | IL212664A0 (enExample) |
| WO (1) | WO2010051882A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015069489A1 (en) | 2013-11-06 | 2015-05-14 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
| KR101712982B1 (ko) * | 2015-07-31 | 2017-03-07 | 고려대학교 산학협력단 | 비알콜성지방간 조절인자 14-3-3 단백질 |
| WO2018148638A1 (en) * | 2017-02-10 | 2018-08-16 | Zafgen, Inc. | Pharmaceutical compositions of metap-2 inhibitors |
| CN108611352B (zh) * | 2018-04-20 | 2020-08-07 | 华南农业大学 | 一种拟禾本科根结线虫翻译延长因子Mg-eEF1A及其防治植物病害的应用 |
| CA3170118A1 (en) * | 2020-02-06 | 2021-08-12 | The Regents Of The University Of California | Elongation factor 1-alpha inhibitors and uses thereof |
| CN116395718B (zh) * | 2023-04-12 | 2024-12-17 | 中国科学院长春应用化学研究所 | 一种弱碱性钠盐纳米药物、其制备方法及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998056372A1 (en) * | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
| EP1337854A2 (en) * | 2000-11-14 | 2003-08-27 | Novartis AG | Method for screening anti-proliferative compounds and inhibiting tumor growth |
| US20020182701A1 (en) * | 2001-08-30 | 2002-12-05 | Saint Louis University | Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof |
| US20030232383A1 (en) | 2001-11-02 | 2003-12-18 | Sylvia Daunert | Novel reagentless sensing system for measuring carbohydrates based on the galactose/glucose binding protein |
-
2009
- 2009-10-05 WO PCT/EP2009/007102 patent/WO2010051882A1/en not_active Ceased
- 2009-10-05 AU AU2009313167A patent/AU2009313167C1/en active Active
- 2009-10-05 ES ES09778819T patent/ES2402564T3/es active Active
- 2009-10-05 JP JP2011533565A patent/JP5347028B2/ja active Active
- 2009-10-05 EP EP09778819A patent/EP2344665B1/en active Active
- 2009-10-05 US US13/127,834 patent/US9151743B2/en active Active
- 2009-10-05 CA CA2742737A patent/CA2742737C/en active Active
-
2011
- 2011-05-03 IL IL212664A patent/IL212664A0/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| Grant AG et al. Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells. Int J Cancer. 1992 Mar 12;50(5):740-5 * |
| Warder SE et al. Discovery, identification, and characterization of candidate pharmacodynamic markers of methionine aminopeptidase-2 inhibition. J Proteome Res. 2008 Nov;7(11):4807-20. Epub 2008 Oct 2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110275088A1 (en) | 2011-11-10 |
| EP2344665B1 (en) | 2013-01-23 |
| IL212664A0 (en) | 2011-07-31 |
| AU2009313167A1 (en) | 2011-06-23 |
| US9151743B2 (en) | 2015-10-06 |
| JP5347028B2 (ja) | 2013-11-20 |
| ES2402564T3 (es) | 2013-05-06 |
| CA2742737C (en) | 2018-05-29 |
| CA2742737A1 (en) | 2010-05-14 |
| JP2012507268A (ja) | 2012-03-29 |
| WO2010051882A1 (en) | 2010-05-14 |
| EP2344665A1 (en) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8119355B2 (en) | Biomarkers for cancer sensitivity and uses thereof | |
| US20070292869A1 (en) | Compositions and Methods for Analyzing Renal Cancer | |
| AU2009313167C1 (en) | Use of EEF1A as biomarker for screening of MetAP2 inhibitors | |
| EP2620770B1 (en) | Novel testing method for angiitis | |
| JP6826543B2 (ja) | アルツハイマー病に関係する生体分子 | |
| JP6588893B2 (ja) | 卵巣がんの自己抗体バイオマーカー | |
| AU2009313167B2 (en) | Use of EEF1A as biomarker for screening of MetAP2 inhibitors | |
| CN104364649B (zh) | 用于鉴定具有基因毒性的化合物的蛋白表达分析 | |
| WO2012052074A2 (en) | Novel biomarkers of liver cancer | |
| US20130287801A1 (en) | Biomarkers, uses of biomarkers and a method of identifying biomarkers | |
| JP4515099B2 (ja) | Ｌａｓｐ−１免疫反応性の決定によって炎症性疾患および感染を診断するための方法 | |
| WO2011009523A1 (en) | Eg5 as biomarker in rare thoracic cancer | |
| US9977026B2 (en) | Detection of elevated levels of phosphorylated MCM and method of increasing MCM phosphorylation capacity | |
| EP4075141A2 (en) | Method for predicting reactivity to drug targeting bcl2 family protein | |
| US20130309255A1 (en) | Biomarkers, uses of biomarkers and a method of identifying biomarkers | |
| WO2025245122A1 (en) | Reducing soluble mesothelin by plasma exchange | |
| CN119548517A (zh) | 一种m2巨噬细胞的诱导剂及应用 | |
| JP2017515108A (ja) | 肉腫の転移を検出するための方法およびバイオマーカー | |
| WO2007037532A9 (ja) | Ｓｒｍｓ遺伝子の治療的又は診断的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 FEB 2014 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 FEB 2014 |
|
| FGA | Letters patent sealed or granted (standard patent) |